Company: ARWR
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001628280-25-024666
Chunk: 53

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 53
---
, European Union, Japan and China.The Financing Agreement contains certain embedded features that were identified and evaluated as not material to the consolidated financial statements.The outstanding balance of the Credit Facility consisted of the following:March 31, 2025September 30, 2024(in thousands)Initial Term Loan$400,000 $400,000 Accumulated interest on the Initial Term Loan39,687 9,000 Less: Unamortized debt discount and issuance costs(14,135)(15,817)Less: Current portion of credit facility(65,000)— Less: Payments(151,625)— Credit facility, net of current portion$208,927 $393,183 The following table sets forth total interest expense recognized related to the Credit Facility:Three Months Ended March 31,Six Months Ended March 31,2025202420252024(in thousands)Amortization of debt discount and issuance costs$1,129 $— $1,682 $— Contractual interest expense15,009 — 30,687 — Total interest expense$16,138 $— $32,369 $— The amounts shown in the table below, related to the Credit Facility, represent the maximum payments the Company is obligated to make to the Lenders during the indicated periods. Principal repayment of up to $160.0 million is scheduled through the fifth year, in line with the contractual terms of the Credit Facility. Actual payments may vary and could be lower than the amounts presented in the table. 

21

YearAmounts(in thousands)2025 (remainder)$50,000 202640,000 202740,000 202815,000 202915,000 Thereafter203,063 Total$363,063 

NOTE 13. NET INCOME (LOSS) PER SHARE

The following table presents the computation of basic and diluted net income (loss) per share for the three and six months ended March 31, 2025 and 2024.                            Three Months Ended March 31,Six Months Ended March 31,2025202420252024(in thousands, except per share amounts)Numerator:Net income (loss) attributable to Arrowhead Pharmaceuticals, Inc.$370,445 $(125,300)$197,360 $(258,164)Denominator:Weighted-average basic shares outstanding (1)133,363 123,285 129,059 115,307